Abstract 1745P
Background
Treatment abandonment (TA) is a major challenge in cancer care leading to poor outcomes and wastage of resources. Reasons for TA are multi-factorial and country specific. Understanding these complexities is the first step toward developing effective strategies for the prevention of TA. Insights and experiences of healthcare workers (HCWs) can provide valuable information about the factors contributing to TA; hence we conducted a qualitative study to understand the issues.
Methods
The participants were purposively selected, experienced HCWs (N=30) treating cancer patients from high-volume cancer centres nationwide. In-depth interviews (semi-structured, open-ended) were conducted by a person trained and experienced in qualitative interviews to understand the perspectives of HCWs on TA among adult cancer patients. We used the grounded theory approach to thematically analyze the data using inductive analysis.
Results
The HCWs (oncologists=17, nurses=6, psycho-oncologists=3, counselors=4) were selected from 9 states of India representing all geographical regions and working in both private (paid services, N= 14) and government (free services, N=16) sectors. The average duration of the interview was 30 minutes, and the reasons for TA perceived by the HCWs were classified under 6 themes: 1) Socio-demographic, 2) Patient-specific, 3) Clinical, 4) Psychological, 5) Health system related, and 6) Economic factors. Catastrophic health expenditure, direct medical and/or non-medical costs, indirect medical costs, poor socio-economic status, lack of specific knowledge about disease and treatment, poor patient-provider communication, accessibility, psychological distress, and toxicities of treatment were the common reasons for TA cited by the HCWs.
Conclusions
The study is one of the first studies reporting on HCWs’ perspective on TA among cancer patients in India. In addition to well-known socio-economic factors, this study identified important themes such as lacunae in communication and psychological issues (e.g., distress) causing TA. The results of this study will help plan quantitative research into the complex issues of TA and interventions to counter the problem.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
P. Ganesan.
Funding
Indian Council of Medical Research-ICMR, New Delhi, India.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1912TiP - STELLAR-304: A randomized phase III study of zanzalintinib (XL092) and nivolumab in non-clear cell renal cell carcinoma (nccRCC)
Presenter: Sumanta Pal
Session: Poster session 23
2366P - Phase I-II study of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial)
Presenter: Daniel Castellano Gauna
Session: Poster session 23
2367P - A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Russells Pachynski
Session: Poster session 23
2368P - Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial
Presenter: Patrizia Giannatempo
Session: Poster session 23
2369P - Phase II study of nivolumab (nivo) and ipilimumab (ipi) for advanced bladder cancer with variant histologies (BCVH)
Presenter: Bradley McGregor
Session: Poster session 23
2370P - Updated results of PEANUT trial: Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Achille Bottiglieri
Session: Poster session 23
2371P - Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts)
Presenter: Shilpa Gupta
Session: Poster session 23
2372P - Efficacy of a tailored approach with nivolumab (N) and nivolumab+ipilimumab (N+I) as immuno-therapeutic boost in metastatic urothelial carcinoma (mUC): Final results of TITAN-TCC
Presenter: Marc-Oliver Grimm
Session: Poster session 23
2373P - Outcomes by retrospective eligibility for maintenance therapy of patients (pts) with advanced urothelial carcinoma (UC): Post hoc analysis of KEYNOTE-361
Presenter: Ronac Mamtani
Session: Poster session 23
2374P - A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC)
Presenter: Petros Grivas
Session: Poster session 23